Overexpression of the BCRP/MXR/ABCP gene in a topotecan-selected ovarian tumor cell line

Cancer Research

Volumn 59, Issue 18, 1999, Pages 4559-4563

  Maliepaard, Marc ^a   Van Gastelen, Margôt A ^a   De Jong, Laurina A ^a   Pluim, Dick ^a   Van Waardenburg, Robert C A M ^a   Ruevekamp Helmers, Marjan C ^a   Floot, Ben G J ^a   Schellens, Jan H M ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

9 AMINOCAMPTOTHECIN; MITOXANTRONE; TOPOTECAN;

ARTICLE; CARCINOGENESIS; DRUG MECHANISM; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; OVARY TUMOR; PHARMACODYNAMICS; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; ATP-BINDING CASSETTE TRANSPORTERS; CAMPTOTHECIN; DRUG RESISTANCE, MULTIPLE; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KINETICS; MITOXANTRONE; NEOPLASM PROTEINS; OVARIAN NEOPLASMS; TOPOTECAN; TUMOR CELLS, CULTURED;

EID: 0033568540     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Bradley, G., Juranka, P. F., and Ling, V. Mechanism of multidrug resistance. Biochim. Biophys. Acta, 948: 87-128, 1988.
2. Zaman, G. J. R., Flens, M. J., van Leusden, M. R., de Haas, M., Mulder, H. S., Lankelma, J., Pinedo, H. M., Scheper, R. J., Baas, F., Broxterman, H. J., and Borst, P. The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc. Natl. Acad. Sci. USA, 91: 8822-8826, 1994.
3. Kool, M., de Haas, M., Scheffer, G. L., Scheper, R. J., van Eijk, M. J. T., Juijn, J. A., Baas, F., Borst, P., and van Eijk, M. J. Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologs of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res., 57: 3537-3547, 1997.
4. Chu, X. Y., Kato, Y., and Sugiyama, Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. Cancer Res., 57: 1934-1938, 1997.
5. Doyle, L. A., Yang, W., Abruzzo, L. V., Krogmann, T., Gao, Y., Rishi, A. K., and Ross, D. D. A multidrug resistance transporter from MCF-7 breast cancer cells. Proc. Natl. Acad. Sci. USA, 95: 15665-15670, 1998.
6. Ross, D. D., Yang, W., Abruzzo, L. V., Dalton, W. S., Schneider, E., Lage, H., Dietel, M., Greenberger, L., Cole, S. P. C, and Doyle, L. A. Atypical multidrug resistance: breast cancer resistance protein messenger RNA expression in mitoxantrone-selected cell lines. J. Natl. Cancer Inst., 91: 429-433, 1999.
7. Miyake, K., Mickley, L., Litman, T., Zhan, Z., Robey, R., Cristensen, B., Brangi, M., Greenberger, L., Dean, M., Fojo, T., and Bates, S. E. Molecular cloning of cDNAs which are highly overexpressed in mitoxantrone-resistant cells: demonstration of homology to ABC transport genes. Cancer Res., 59: 8-13, 1999.
8. Allikmets, R., Schriml, L. M., Hutchinson, A., Romano-Spica, V., and Dean, M. A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance. Cancer Res., 58: 5337-5339, 1998.
9. Yang, C-H., Horton, J. K., Cowan, K. H., and Schneider, E. Cross-resistance to camptothecin analogues in a mitoxantrone-resistant human breast carcinoma cell line is not due to DNA topoisomerase I. Cancer Res., 55: 4004-4009, 1995.
10. Benard, J., Da Silva, J., De Blois, M-C., Boyer, P., Duvillard, P., Chiric, E., and Riou, G. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res., 45: 4970-4979, 1985.
11. Rubenstein, L. V., Shoemaker, R. H., Paull, K. D., Simon, R. M., Tosini, S., Skehan, P., Scudiero, D. A., Monks, A., and Boyd, M. R. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J. Natl. Cancer Inst., 82: 1113-1118, 1990.
12. Liu, L. F., and Miller, K. G. Eukaryotic DNA topoisomerases: two forms of type I DNA topoisomerases from HeLa cell nuclei. Proc. Natl. Acad. Sci. USA, 78: 3487-3491, 1981.
13. van der Zee, A. G. J., Hollema, H., de Jong, S., Boonstra, H., Gouw, A., Willemse, P. H. B., Zijlstra, J. G., and de Vries, E. G. E. P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res., 51: 5915-5920, 1991.
14. Miller, K. G., Liu, L. F., and Englund, P. T. A homogeneous type II DNA topoisomerase from HeLa cell nuclei. J. Biol. Chem., 256: 9334-9339, 1981.
15. Paulusma, C. C., Bosma, P. J., Zaman, G. J., Bakker, C. T., Otter, M., Scheffer, G. L., Scheper, R. J., Borst, P., and Oude Elferink, R. P. Congenital jaundice in rats with a mutation in a multidrug resistance-associated protein gene. Science (Washington DC), 271: 1126-1128, 1996.
16. Rosing, H., Doyle, E., Davies, B. E., and Beijnen, J. H. High-performance liquid chromatographic determination of the novel antitumour drug topotecan and topotecan as the total of the lactone plus carboxylate forms, in human plasma. J. Cnromatogr. B Biomed. Appl., 668: 107-115, 1995.
17. Ma, J., Maliepaard, M., Nooter, K., Loos, W. J., Kolker, H. J., Verweij, J., Stoter, G., and Schellens, J. H. M. Reduced cellular accumulation of topotecan: a novel mechanism of resistance in a human ovarian cancer cell line. Br. J. Cancer, 77: 1645-1652, 1998.
18. Versantvoort, C. H. M., Broxterman, H. J., Pinedo, H. M., de Vries, E. G. E., Feller, N., Kuiper, C. M., and Lankelma, J. Energy-dependent processes involved in reduced drug accumulation in multidrug-resistant human lung cancer cell lines without P-glycoprotein expression. Cancer Res., 52: 17-23, 1992.
19. Lundin, A., Hasenson, M., Persson, J., and Pousette, A. Estimation of biomass in growing cell lines by adenosine triphosphate assay. Methods Enzymol., 133: 27-42, 1986.